- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00030108
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young patients with relapsed or refractory solid tumors or leukemia.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
OBJECTIVES:
Primary
- Determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of ixabepilone in young patients with refractory solid tumors (closed to accrual as of 10/4/2007) or relapsed or refractory leukemia.
- Determine the toxicity spectrum of this drug in these patients.
- Determine the plasma pharmacokinetics of this drug in these patients.
- Determine the pharmacodynamics of this drug in these patients.
- Assess the nerve growth factor levels, before and after the initiation of this drug, as a potential surrogate marker for the development of peripheral neuropathy in these patients.
Secondary
- Determine the response of patients treated with this drug.
- Compare the tolerability, toxicity profile, MTD, DLT, pharmacokinetics, and pharmacodynamics of this drug in young patients treated on this study vs adults with solid tumors (closed to accrual as of 10/4/2007) treated on the ongoing Medicine Branch, NCI, phase I study.
- Assess the safety and tolerability of ixabepilone at the solid tumor MTD (expanded leukemia cohort).
- Evaluate the plasma pharmacokinetics of in young patients with refractory or relapsed leukemia.
- Evaluate the extent of tubulin polymerization in leukemic blasts at baseline after treatment with ixabepilone ex-vivo.
- Compare the effects of tubulin polymerization in leukemic blasts with ixabepilone versus paclitaxel ex-vivo with an without the presence of a potent P-glycoprotein inhibitor.
- Evaluate the activity known drug transporters in drug-resistant leukemias in leukemic blasts.
OUTLINE: This is a multicenter, dose-escalation study.
Patients receive ixabepilone IV over 1 hour on days 1-5. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience dose-limiting toxicity. Intrapatient dose escalation to one dose level above the enrollment dose level is allowed in patients who have stable or responding disease or are experiencing other benefits from therapy (e.g., decrease in tumor-related pain symptoms) and who have no grade 2 or greater non-hematologic toxicity and no grade 3 or greater hematologic toxicity. Additional patients are treated at the MTD. Patients treated at the MTD may not undergo intrapatient dose escalation.
PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study within 1-2 years.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos, 20010-2970
- Children's National Medical Center
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20892-1182
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
DISEASE CHARACTERISTICS:
Meets 1 of the following criteria:
Histologically confirmed solid tumor (closed to accrual as of 10/4/2007) that relapsed after or failed to respond to front-line curative therapy and for which no other potentially curative treatment options exist
- Curative therapy may include surgery, radiotherapy, chemotherapy, or any combination of these modalities
Eligible tumor types include, but are not limited to, the following:
- Rhabdomyosarcoma
- Other soft tissue sarcomas
- Ewing's sarcoma family of tumors
- Osteosarcoma
- Neuroblastoma
- Wilms' tumor
- Hepatic tumors
- Germ cell tumors
Primary brain tumors
- Histologic confirmation may be waived for brain stem or optic glioma
Diagnosis of relapsed or refractory leukemia
- Patients with refractory or second or greater relapsed leukemia must have > 25% blasts in the bone marrow (M3 bone marrow) with or without active extramedullary disease (except for leptomeningeal disease)
- Relapsed after or failed to respond to frontline curative therapy and no other potentially curative therapy (e.g., radiotherapy, chemotherapy, or any combination of these modalities) exists
- Patients with acute promyelocytic leukemia must be refractory to treatment with retinoic acid and arsenic trioxide
- Patients with Philadelphia chromosome positive chronic myelogenous leukemia must be refractory to imatinib
- No active CNS leukemia (CNS3)
PATIENT CHARACTERISTICS:
Age:
- 2 to 18 (solid tumor patients [closed to accrual as of 10/4/2007])
- 1 to 21 (leukemia patients)
Performance status:
For patients age 11 to 21:
- Karnofsky 50-100%
For patients age 1 to 10:
- Lansky 50-100%
Life expectancy:
- Not specified
Hematopoietic:
- Platelet count at least 100,000/mm^3 (20,000/mm^3 for leukemia patients)
- Hemoglobin ≥ 8.0 g/dL
Hepatic:
- Bilirubin less than 1.5 times upper limit of normal (ULN)
- SGOT and SGPT less than 2.5 times ULN
- No hepatic dysfunction that would preclude study
Renal:
- Creatinine normal for age OR
- Creatinine clearance at least 60 mL/min
- No renal dysfunction that would preclude study
Other:
- No known severe prior hypersensitivity reaction to agents containing Cremophor EL
- No clinically significant unrelated systemic illness (e.g., serious infections or other organ dysfunction) that would preclude study
- No grade 2 or greater preexisting sensory neuropathy
- More than 2 month since prior and no concurrent evidence of graft vs host disease
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Recovered from all therapy-related acute toxic effects (leukemia patients only)
- Prior epoetin alfa allowed
- At least 3 days since other prior colony-stimulating factors (e.g., filgrastim (G-CSF), sargramostim (GM-CSF), or interleukin-11 (IL-11))
- At least 6 months since prior bone marrow transplantation
- At least 2 months since prior stem cell transplantation or rescue (leukemia patients)
- At least 7 days since prior therapy with a biological agent and hematopoietic growth factor with the exception of erythropoietin
- More than 3 weeks since prior monoclonal antibody therapy (leukemia patients only)
- No concurrent GM-CSF or IL-11
- No concurrent immunotherapy
Chemotherapy:
- See Disease Characteristics
- Recovered from all therapy-related acute toxic effects (leukemia patients only)
- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
- No other concurrent anticancer chemotherapy
Endocrine therapy:
- Concurrent corticosteroids allowed for the control of symptoms related to tumor-associated edema in patients with brain tumors
- Patients with brain tumors must be on a stable or tapering dose of corticosteroids for 7 days before baseline scan is performed for the purpose of assessing response to study therapy
- Must be on a stable or tapering dose of corticosteroids for 7 days prior to study entry (leukemia patients only)
Radiotherapy:
- See Disease Characteristics
- Recovered from all therapy-related acute toxic effects (leukemia patients only)
- At least 4 weeks since prior radiotherapy
- More than 2 weeks since prior local palliative radiotherapy (leukemia patients only)
- More than 3 months since prior total-body irradiation, craniospinal radiotherapy, or radiotherapy to ≥50% of the pelvis (leukemia patients only)
- More than 6 weeks since prior other substantial bone marrow radiotherapy (leukemia patients only)
- No prior extensive radiotherapy (e.g., craniospinal irradiation, total body irradiation, or radiotherapy to more than half of the pelvis)
- No concurrent anticancer radiotherapy
Surgery:
- See Disease Characteristics
Other:
- Recovered from prior therapy
- At least 30 days since any prior investigational anticancer therapy
At least 1 week since prior known inhibitors of CYP3A4, including any of the following:
- Antibiotics (i.e., clarithromycin, erythromycin, or troleandomycin)
- Anti-HIV agents (i.e, delaviridine, nelfinavir, amprenavir, ritonavir, idinavir, saquinavir, or lopinavir)
- Anti-fungals (i.e., itraconazole, ketoconazole, fluconazole [doses > 3mg/kg/day], or voriconazole)
- Anti-depressants (i.e., nefaxodone or fluovoxamine)
- Calcium channel blockers (i.e., verapamil or diltiazem)
- Anti-emetics (i.e., aprepitant [Emend®])
- Miscellaneous agents (i.e., amiodarone)
- Grapefruit juice
- No other concurrent investigational agents
- No concurrent St. John's Wort
- No concurrent known inhibitors of CYP3A4, including grapefruit juice
- Concurrent other agents inducing CYP3A4 allowed
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
|---|
|
Maximum tolerated dose and dose-limiting toxicity of ixabepilone
|
|
Toxicity spectrum
|
|
Plasma pharmacokinetics
|
|
Farmacodinâmica
|
|
Nerve growth factor levels before and after drug administration
|
Medidas de resultados secundários
Medida de resultado |
|---|
|
Resposta objetiva do tumor
|
|
Tubulin polymerization in PBMCs prior to the start of the infusion, just before the end of the infusion, 5 hours after the end of the infusion and before the start of the infusion on day 2 of the ixabepilone on course 1
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Cadeira de estudo: AeRang Kim, MD, National Cancer Institute (NCI)
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
- tumor sólido infantil não especificado, protocolo específico
- L3 Leucemia Linfoblástica Aguda na Infância
- Leucemia linfoblástica aguda infantil de células B
- leucemia mielóide aguda infantil em remissão
- Leucemia Mielóide Crônica na Infância
- leucemia mielóide crônica, BCR-ABL1 positivo
- rabdomiossarcoma infantil previamente tratado
- rabdomiossarcoma infantil recorrente
- neuroblastoma recorrente
- leucemia linfoblástica aguda recorrente na infância
- L1 Leucemia Linfoblástica Aguda na Infância
- Leucemia linfoblástica aguda L2 na infância
- leucemia mielóide aguda recorrente na infância
- sarcoma de Ewing recorrente/tumor neuroectodérmico primitivo periférico
- osteossarcoma recorrente
- tumor de Wilms recorrente e outros tumores renais da infância
- leucemia promielocítica aguda da infância (M3)
- oligodendroglioma infantil
- astrocitoma cerebelar infantil recorrente
- astrocitoma cerebral infantil recorrente
- ependimoma infantil recorrente
- câncer de fígado infantil recorrente
- sarcoma recorrente de tecidos moles na infância
- meduloblastoma infantil recorrente
- Via visual infantil recorrente e glioma hipotalâmico
- craniofaringioma infantil
- tumor de células germinativas do sistema nervoso central na infância
- tumor de células germinativas na infância
- tumor do plexo coróide na infância
- meningioma grau I da infância
- meningioma grau II da infância
- meningioma grau III da infância
- teratoma infantil
- tumor de células germinativas testiculares maligno da infância
- tumor maligno de células germinativas ovarianas na infância
- tumor extragonadal de células germinativas na infância
- tumor de células germinativas maligno recorrente na infância
- leucemia basofílica aguda infantil
- Leucemia Eosinofílica Aguda na Infância
- Leucemia linfoblástica aguda na infância
- leucemia linfoblástica aguda infantil não-T, não-B, cALLa negativa
- leucemia linfoblástica aguda infantil não-T, não-B, cALLa positiva
- leucemia linfoblástica aguda infantil não-T, não-B, cALLa positiva, pré-B
- Leucemia linfoblástica aguda infantil TdT negativa
- Leucemia linfoblástica aguda infantil TdT positiva
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Doenças do Sistema Nervoso
- Neoplasias de Tecidos Conjuntivos e Moles
- Neoplasias por Tipo Histológico
- Neoplasias por local
- Neoplasias Glandulares e Epiteliais
- Neoplasias do Aparelho Digestivo
- Doenças do Fígado
- Neoplasias Neuroepiteliais
- Tumores Neuroectodérmicos
- Neoplasias, Tecido Nervoso
- Tumores Neuroectodérmicos Primitivos
- Tumores Neuroectodérmicos Primitivos Periféricos
- Neoplasias
- Sarcoma
- Neoplasias, Células Germinativas e Embrionárias
- Leucemia
- Neoplasias do Sistema Nervoso
- Neoplasias do Sistema Nervoso Central
- Neoplasias Hepáticas
- Neuroblastoma
Outros números de identificação do estudo
- 020031
- 02-C-0031
- NCI-5425
- CDR0000069133
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .